De novo hepatitis B virus infection developing after liver transplantation using a graft positive for hepatitis B core antibody.
10.4174/astr.2015.89.3.145
- Author:
Jae Hyun HAN
1
;
Dong Goo KIM
;
Gun Hyung NA
;
Eun Young KIM
;
Soo Ho LEE
;
Tae Ho HONG
;
Young Kyoung YOU
;
Jong Young CHOI
;
Seung Kew YOON
Author Information
1. Department of Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. kimdg@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatitis B antibodies;
de novo hepatitis B;
Liver transplantation;
Prognosis
- MeSH:
DNA;
Hepatitis B Antibodies;
Hepatitis B Surface Antigens;
Hepatitis B virus*;
Hepatitis B*;
Hepatitis*;
Humans;
Immunoglobulins;
Liver Transplantation*;
Liver*;
Prognosis;
Recurrence;
Retrospective Studies;
Survival Rate;
Tissue Donors;
Transplants*
- From:Annals of Surgical Treatment and Research
2015;89(3):145-150
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The use of hepatitis B core antibody (HBcAb)-positive grafts is increasing, especially where hepatitis B is endemic. However, this remains controversial because of the risk of development of de novo HBV infection. METHODS: We collected information obtained between January 2000 and December 2012 and retrospectively analyzed data on 187 HBsAg-negative donors and recipients were analyzed retrospectively. De novo HBV infection was defined as development of HBsAg positivity with or without detection of HBV DNA. RESULTS: Forty patients (21.4%) received HBcAb-positive grafts. Survival rate did not differ by donor HBcAb status (P = 0.466). De novo HBV infection occurred in five patients (12.5%) who were not treated with anti-HBV prophylaxis, and was significantly more prevalent in hepatitis B surface antibody (HBsAb)- and HBcAb-negative than HBsAb- and HBcAb-positive recipients (50% vs. 4.2%, P = 0.049). All patients except one were treated with entecavir with/without antihepatitis B immunoglobulin and four were negative in terms of HBV DNA seroconversion. No patient died. CONCLUSION: HBcAb-positive grafts are safe without survival difference. However, the risk of de novo hepatitis B virus infection was significantly increased in HBsAb- and HBcAb-negative recipients. All patients were successfully treated even after recurrence.
